Psoriasis
Not recruitingORKA-001 in Patients with Moderate-to-Severe Plaque Psoriasis
ORKA-001 in Patients with Moderate-to-Severe Plaque Psoriasis
Germany- Participants:18–64 years · 65+ years
- Substances:ORKA-001
- Sponsor:Oruka Therapeutics Inc.
Rare diseases
Investigational molecules
Locations
Back to Germany1 664 clinical trials in Darmstadt, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)ORKA-001 in Patients with Moderate-to-Severe Plaque Psoriasis
GermanyRO7795068 for Weight Loss in Adults With Obesity or Overweight Without Type 2 Diabetes
GermanyBaricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis
GermanyEfficacy and Safety of MET097 Once Weekly in People with Overweight or Obesity and Type 2 Diabetes
GermanyA study to evaluate the efficacy and safety of MET097 in people with obesity or overweight.
GermanyA study to evaluate the safety and effectiveness of galvokimig in adults with moderate to severe atopic dermatitis
GermanyA study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)
GermanyStudy of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease
GermanyA study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia
GermanyA study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease
GermanyTesting Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned
GermanyA Study of KT-621 Tablets Taken by Mouth for Adults with Moderate to Severe Atopic Dermatitis
GermanyThe busiest research cities in the country
What the registry says about research in the country
Extensive research focusing on plaque psoriasis and hidradenitis suppurativa, evaluating new therapeutic approaches for chronic skin conditions. Multiple trials are testing novel treatments for moderate to severe cases.
Several innovative compounds being tested including ESK-001, remibrutinib, and JNJ-77242113.
Comprehensive studies addressing severe asthma and COPD, with particular attention to treatments for patients with eosinophilic phenotypes and those requiring advanced care options.
Trials evaluating new inhalation therapies and biological treatments for better disease control.
Advanced studies in acute myeloid leukemia, investigating combination therapies for patients ineligible for intensive chemotherapy. Focus on targeted treatments for specific genetic mutations.
Investigating innovative approaches including revumenib in combination with established treatments.
Tell us about your condition – we search every trial in Europe and connect you with the right site.